3SBio Inc. (FRA:83B)

Germany flag Germany · Delayed Price · Currency is EUR
2.140
-0.020 (-0.93%)
At close: Jun 5, 2025, 10:00 PM CET
205.71%
Market Cap 5.33B
Revenue (ttm) 1.21B
Net Income (ttm) 276.61M
Shares Out n/a
EPS (ttm) 0.11
PE Ratio 19.28
Forward PE 18.33
Dividend 0.03 (1.37%)
Ex-Dividend Date Jul 22, 2024
Volume 150
Average Volume 1,033
Open 2.100
Previous Close 2.160
Day's Range 2.100 - 2.140
52-Week Range 0.570 - 2.440
Beta n/a
RSI 65.54
Earnings Date May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1993
Employees 5,577
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 83B
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.